CX-5461 | Pidnarulex | 1138549-36-6

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
2 mg	3-5days	$56.00	Visible after login	- +
5 mg	3-5days	$88.00	Visible after login	- +
10 mg	3-5days	$156.00	Visible after login	- +
25 mg	3-5days	$288.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

2 mg

3-5days

$56.00

Visible after login

- +

5 mg

3-5days

$88.00

Visible after login

- +

10 mg

3-5days

$156.00

Visible after login

- +

25 mg

3-5days

$288.00

Visible after login

- +

Product Overview

Product Name	CX-5461 \| Pidnarulex
CAS	1138549-36-6
Formula	C27H27N7O2S
MW	513.61
Appearance	White to yellow powder
Storage condition	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Product details

CX-5461 is a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage. CX-5461 selectively inhibits rRNA synthesis by Pol I in the nucleolus, but does not inhibit mRNA synthesis by RNA Polymerase II (Pol II) and does not inhibit DNA replication or protein synthesis. Inhibition of Pol I results in nucleolar stress and release of ribosomal proteins (RP) from the nucleolus. The RP bind to Mdm2 and liberate p53 to orchestrate apoptosis in cancer cells. CX-5461 demonstrates a favorable preclinical profile, potently and selectively kills cancer cells, demonstrates robust in vivo efficacy in multiple models, and has demonstrated oral bioavailability in multiple species.

Related literature

Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth.

PMID: 21159662 DOI: 10.1158/0008-5472.CAN-10-1728

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53.

PMID: 22789538 PMCID: PMC3749732 DOI: 10.1016/j.ccr.2012.05.019